Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Stereotactic Radiotherapy in Tumor Ablation
share announcement

Stereotactic Radiotherapy in Tumor Ablation

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 6037

Special Issue Editors

Dr. Rémy Kinj

E-Mail Website
Guest Editor
Service of Radiation Oncology, Department of Oncology, Lausanne University Hospital, 1010 Lausanne, Switzerland
Interests: stereotactic body radiotherapy; re-irradiation; lattice radiotherapy; thoracic radiotherapy
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Jean Bourhis

E-Mail Website
Guest Editor
Department of Radiation Oncology, Lausanne University Hospital, CH-1205 Lausanne, Switzerland
Interests: head and neck radiotherapy; flash radiotherapy; stereotactic body radiotherapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We would like to cordially invite you to contribute to the collection of articles related to "stereotactic radiotherapy in tumor ablation".

In the last decade, we have seen a growing interest in oncology for stereotactic body radiotherapy (SBRT), which appears as a highly effective, non-invasive, and safe tumor ablative treatment.

SBRT is building on major improvements in delivery achieved by intensity-modulated and image-guided radiotherapy, now allowing safe ablative doses of radiation to be delivered. SBRT is increasingly used to treat a variety of cancers including the treatment of primary tumors as well as metastases in a wide range of locations (brain, bone, lung, prostate, liver, etc.).

Accumulated clinical evidence is growing over time, with efficacy and safety being proven in randomized clinical trials.

This collection of articles aims to provide a comprehensive and broad overview of the use of SBRT in the central nervous system, head and neck, thorax, abdomen, and pelvis as well as its use in re-irradiation or metastatic and oligometastatic settings. Discussions on the technical evolutions, biological background, new developments, and potential limitations are encouraged. The remarkable complementarity of SBRT with systemic treatments is also important to emphasize.

Our goal is to create a reliable and updated source of information for all physicians and oncologists and to improve cancer care through the use of this cutting-edge technology.

We look forward to receiving your contributions to this Special Issue of the journal Cancers.

Dr. Rémy Kinj
Prof. Dr. Jean Bourhis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • SBRT
  • stereotactic body radiotherapy
  • SABR
  • stereotactic ablative radiotherapy
  • re-irradiation
  • oligometastasis
  • local therapy

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Research, Review

4 pages, 1261 KiB  
Editorial
How Stereotactic Radiotherapy Changed the Landscape in Cancer Care
by Rémy Kinj and Jean Bourhis
Cancers 2023, 15(6), 1734; https://doi.org/10.3390/cancers15061734 - 13 Mar 2023
Cited by 3 | Viewed by 2470
Abstract
The term “stereotactic body radiotherapy” (SBRT) refers to high-precision radiotherapy techniques using numerous beams converging in a small target volume, allowing the delivery of high doses per fraction (>6–7 Gy) in a very few number of fractions [...] Full article
(This article belongs to the Special Issue Stereotactic Radiotherapy in Tumor Ablation)
►▼ Show Figures

Figure 1

Research

Jump to: Editorial, Review

14 pages, 1105 KiB  
Article
Impact of Waiting Response Evaluation to First-Line Systemic Therapy before Considering Local Ablative Therapy in Metastatic Non-Small-Cell Lung Cancer
by Lahcene Belaidi, Pascal Wang, Kevin Quintin, Catherine Durdux, Etienne Giroux-Leprieur and Philippe Giraud
Cancers 2023, 15(21), 5127; https://doi.org/10.3390/cancers15215127 - 25 Oct 2023
Viewed by 885
Abstract
Stereotactic radiotherapy (SRT) is gaining increasing importance in metastatic non-small-cell lung cancer (mNSCLC) management. The optimal sequence of tumor irradiation relative to systemic treatment remains unclear. If waiting response evaluation to first-line systemic therapy (FLST) before considering local treatment may allow for the [...] Read more.
Stereotactic radiotherapy (SRT) is gaining increasing importance in metastatic non-small-cell lung cancer (mNSCLC) management. The optimal sequence of tumor irradiation relative to systemic treatment remains unclear. If waiting response evaluation to first-line systemic therapy (FLST) before considering local treatment may allow for the exclusion of poorer prognosis progressive tumors that may not benefit from SRT, performing irradiation near immune check point inhibitor (ICI) first administration seems to improve their synergic effect. Herein, we aimed to determine whether delaying SRT after response evaluation to FLST would result in better prognosis. We compared overall survival (OS), progression-free survival (PFS), and time to first subsequent therapy (TFST) for 50 patients locally treated before or within 90 days of initiating FLST (early SRT), with 49 patients treated at least 90 days after initiating FLST (late SRT). Patients treated with conventional chemotherapy alone exhibited significantly poorer median OS, PFS, and TFST in the early SRT arm: (in months) 16.5 [8.33-NR] vs. 58.3 [35.05-NR] (p = 0.0015); 4.69 [3.57–8.98] vs. 8.20 [6.66–12.00] (p = 0.017); and 6.26 [4.82–11.8] vs. 10.0 [7.44–21.8] (p = 0.0074), respectively. Patient receiving ICI showed no difference in OS (NR [25.2-NR] vs. 36.6 [35.1-NR], p = 0.79), PFS (7.54 [6.23-NR] vs. 4.07 [2.52-NR], p = 0.19), and TFST (13.7 [9.48-NR] vs. 10.3 [3.54-NR], p = 0.49). These results suggest that delaying SRT treatment in order to filter a rapidly growing tumor may be less necessary when ICI is administered in mNSCLC. Full article
(This article belongs to the Special Issue Stereotactic Radiotherapy in Tumor Ablation)
►▼ Show Figures

Figure 1

Review

Jump to: Editorial, Research

26 pages, 1847 KiB  
Review
Stereotactic Radiosurgery and Stereotactic Fractionated Radiotherapy in the Management of Brain Metastases
by Sofian Benkhaled, Luis Schiappacasse, Ali Awde and Remy Kinj
Cancers 2024, 16(6), 1093; https://doi.org/10.3390/cancers16061093 - 8 Mar 2024
Viewed by 799
Abstract
The management of brain metastases (BM) remains an important and complex issue in the treatment of cancer-related neurological complications. BM are particularly common in patients diagnosed with lung, melanoma, or breast cancer. Over the past decade, therapeutic approaches for the majority of BM [...] Read more.
The management of brain metastases (BM) remains an important and complex issue in the treatment of cancer-related neurological complications. BM are particularly common in patients diagnosed with lung, melanoma, or breast cancer. Over the past decade, therapeutic approaches for the majority of BM patients have changed. Considering and addressing the fact that patients with BM are living longer, the need to provide effective local control while preserving quality of life and neurocognition is fundamental. Over the past decade, SRS and SRT have become a more commonly chosen treatment option for BM. Despite significant advances in the treatment of BM, numerous questions remain regarding patient selection and optimal treatment sequencing. Clinical trials are critical to advancing our understanding of BM, especially as more therapeutic alternatives become available. Therefore, it is imperative for interdisciplinary teams to improve their understanding of the latest advances in SRS-SRT. This review aims to comprehensively explore SRS and SRT as treatments for BM, covering clinical considerations in their application (e.g., patient selection and eligibility), managing limited and multiple intact BM, addressing brainstem metastases, exploring combination therapies with systemic treatments, and considering the health economic perspective. Full article
(This article belongs to the Special Issue Stereotactic Radiotherapy in Tumor Ablation)
►▼ Show Figures

Figure 1

11 pages, 702 KiB  
Review
Oligometastatic Disease (OMD): The Classification and Practical Review of Prospective Trials
by Timur Izmailov, Sergey Ryzhkin, Gleb Borshchev and Sergei Boichuk
Cancers 2023, 15(21), 5234; https://doi.org/10.3390/cancers15215234 - 31 Oct 2023
Viewed by 1434
Abstract
Oligometastatic disease (OMD) is currently known as an intermediate state of cancer, characterized by a limited number of systemic metastatic lesions for which local ablative therapy could be curative. Indeed, data from multiple clinical trials have illustrated an increase in overall survival (OS) [...] Read more.
Oligometastatic disease (OMD) is currently known as an intermediate state of cancer, characterized by a limited number of systemic metastatic lesions for which local ablative therapy could be curative. Indeed, data from multiple clinical trials have illustrated an increase in overall survival (OS) for cancer patients when local ablative therapy was included in the systemic adjuvant therapy. Given that no driver and somatic mutations specific to OMD are currently established, the diagnosis of OMD is mainly based on the results of X-ray studies. In 2020, 20 international experts from the European Society for Radiotherapy and Oncology (ESTRO) and the European Organization for Research and Treatment of Cancer (EORTC) developed a comprehensive system for the characterization and classification of OMD. They identified 17 OMD characteristics that needed to be assessed in all patients who underwent radical local treatment. These characteristics reflect the tumor biology and clinical features of the disease underlying the development of OMD independently of the primary tumor type and the number of metastatic lesions. In particular, the system involves the characteristics of the primary tumor (e.g., localization, histology, TNM stage, mutational status, specific tumor markers), clinical parameters (e.g., disease-free interval, treatment-free interval), therapies (e.g., local, radical or palliative treatment, the numbers of the therapeutic regimens), and type of OMD (e.g., invasive). Based on the aforementioned criteria, an algorithm was introduced into the clinic to classify OMDs collectively according to their nomenclature. A history of polymetastatic disease (PMD) prior to OMD is used as a criterion to delineate between induced OMD (previous history of PMD after successful therapy) and genuine OMD (no history of PMD). Genuine OMD is divided into two states: recurrent OMD (i.e., after a previous history of OMD) and de novo OMD (i.e., a first newly diagnosed oligometastatic disease). de novo OMD is differentiated into synchronous and metachronous forms depending on the length of time from the primary diagnosis to the first evidence of OMD. In the case of synchronous OMD, this period is less than 6 months. Lastly, metachronous and induced OMD are divided into oligorecurrence, oligoprogression, and oligopersistence, depending on whether OMD is firstly diagnosed during an absence (oligo recurrence) or presence (oligoprogression or oligopersistence) of active systemic therapy. This classification and nomenclature of OMD are evaluated prospectively in the OligoCare study. In this article, we present a practical review of the current concept of OMD and discuss the available prospective clinical trials and potential future directions. Full article
(This article belongs to the Special Issue Stereotactic Radiotherapy in Tumor Ablation)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop